On the 31st of August, 2012, FUSCC-CRIKU Joint Symposium on Tumor Biology was successfully held in our center. The symposium is jointly sponsored by Fudan University Shanghai Cancer Center and Kanazawa University Cancer Research Institute. Vice president of Fudan University Medical School Dr. Zhihong Bao, vice president of Kanazawa University Cancer Research Institute Dr. Kunio Matsumoto, President of FUSCC Dr. Xiaomao Guo gave opening speech. Vice president of FUSCC Dr. Jiong Wu hosted the symposium. 6 representatives from these two institutions gave academic lectures.

In July 2010, we have signed the sister institution agreement with Kanazawa University Cancer Research Institute from Japan. After two years collaboration in the field of cancer research, education, talents training, we have gained profound improvement. Today we organize this meeting to deepen our collaboration and the upcoming meeting would be a good beginning to bring further and more opportunity of our cooperation in various fields. The main topics of this symposium are: Tumor Biology and Drug Discovery Targeting HGF-Met by Prof. Kunio Matsumoto; Multiple Roles of the BRCA1 A Complex: DNA Damage Repair, Mammary Duct Morphogenesis and Regulation of Gene Expression by Prof. Xin Hu; Roles of Membrane-Type Matrix Metalloproteinase-1 in Tumor Invasion by Prof. Hiroshi Sato; CD59 Confers Resistance to Antibody-Based Therapy on Cancer Cells by Prof. Weiguo Hu; Molecular Targeted Therapy for Lung Cancer by Prof. Seiji Yano; Cancer Center Tissue Bank Management by Prof. Menghong Sun. 

   
This symposium attracted a great number of audiences. Graduate students from our center and oncology intern training site, Fudan University and its affiliated hospital’s graduate students, Fudan University Shanghai Medical School and Chinese Medical School’s researchers, over 100 audiences joined the symposium; they devoted fully to the heated discussion.
  
It is believed that this symposium will surely bring more communication and collaboration in the future for both sides in the various fields of cancer treatment.